Symptomatic vitreomacular adhesion treatment accepted for review by EMA

Article

Ocriplasmin, a treatment for symptomatic vitreomacular adhesion, has been accepted for review by the European Medicines Agency (EMA).

Ocriplasmin, a treatment for symptomatic vitreomacular adhesion, has been accepted for review by the European Medicines Agency (EMA).

The 2.5 mg/mL solution for injection, developed by ThromboGenics (Leuven, Belgium), prevents retinal distortion and further decreases in vision in VMA patients including macular hole. If ocriplasmin is approved it will be the first pharmacological treatment for VMA including macular hole. The solution will be available in the EU and the US.

The CEO of ThromboGenics, Dr Patrik De Haes, said, “The global ThromboGenics team is proud to have achieved the successful acceptance for review of the European MAA for ocriplasmin, a major corporate milestone. Ocriplasmin is also expected to be filed with the FDA in the US by the end of the year. If approved, ocriplasmin will be the first pharmacological treatment for a condition that is currently only treated via surgery, and only after the patient’s vision has significantly deteriorated."

ThromboGenics completed two Phase II clinical trials for ocrimplasmin. The drug is currently in clinical trials for further vitreoretinal conditions. Dr De Haes said, “We are continuing to make excellent progress in building our commercial organization to educate and support the retina specialist community, with the aim of ensuring ocriplasmin achieves its full therapeutic potential and delivers maximum benefit to patients.”

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.